Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system

Journal of the American Society of Nephrology

Volumn 10, Issue 1 SUPPL. 11, 1999, Pages

  Brown, Lindsay ^a   Duce, Brett ^a   Miric, Goran ^a   Sernia, Conrad ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; CANDESARTAN HEXETIL; CAPTOPRIL; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DEOXYCORTICOSTERONE ACETATE; FIBRONECTIN; RENIN; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032951864     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Katz A: Angiotensin II: Hemodynamic regulator or growth factor? J Mol Cell Cardiol 22: 739-747, 1990
2. Timmermans PBM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD: Angiotensin II receptors and functional correlates. Am J Hypertens 5: 221S-235S, 1992
3. Brilla CG, Zhou G, Matsubara L, Weber KT: Collagen metabolism in cultured adult rat cardiac fibroblasts: Response to angiotensin II and aldosterone. J Mol Cell Cardiol 26: 809-820, 1994
4. Pelouch V, Kolár F, Ostadal B, Milerova M, Cihak R, Widimsky J: Regression of chronic hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and fibrosis: Effect of enalapril. Cardiovasc Drugs Ther 11: 177-185, 1997
5. Ju H, Zhao S, Jassal DS, Dixon IM: Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 32: 223-232, 1997
6. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 27: 341-348, 1993
7. Robert V, Thiem NV, Cheav SL, Mouas C, Swynghedauw B, Delcayre C: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24: 30-36, 1994
8. Wyse B, Waters M, Sernia C: Stimulation of the renin-angiotensin system by growth hormone in Lewis dwarf rats. Am J Physiol 265: E332-E339, 1993
9. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987
10. Matsubara H, Kanasaki M, Murasawa S, Tsukaguchi Y, Nio Y, Inada M: Differential gene expression and regulation of angiotensin II receptor subtypes in rat cardiac fibroblasts and cardiomyocytes in culture. J Clin Invest 93: 1592-1601, 1994
11. Power WJ, Kaufman AH, Merayo-Lloves J, Arrunategui-Correa V, Foster CS: Expression of collagens I, III, IV, and V mRNA in excimer wounded rat cornea: Analysis by semi-quantitative PCR. Curr Eye Res 4: 879-886, 1995
12. Nicoletti A, Heudes D, Hinglais N, Appay M, Phillipe M, Sassy-Prigent C, Bariety J, Michel J: Left ventricular fibrosis in renovascular hypertensive rats: Effect of losartan and spironolactone. Hypertension 26: 101-111, 1995
13. Magnuson VL, Young M, Schattenburg DG, Mancini MA, Chen D, Steffensen B, Klebe RJ: The alternative splicing of fibronectin pre-mRNA is altered during aging and in response to growth factors. J Biol Chem 266: 14654-14662, 1991
14. Mirsky I, Parmley WW: Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circ Res 33: 233-243, 1973
15. Weber KT, Sun Y, Tyagi SC, Cleutjens JPM: Collagen network of the myocardium: Function, structural remodelling and regulatory mechanisms. J Mol Cell Cardiol 26: 279-292, 1994
16. Farhadian F, Contard F, Corbier C, Barrieux A, Pappaport L, Samuel JL: Fibronectin expression during physiological and pathological cardiac growth. J Mol Cell Cardiol 27: 981-990, 1995
17. Mamuya WS, Brecher P: Fibronectin expression in the normal and hypertrophic rat heart. J Clin Invest 89: 392-401, 1992
18. Young M, Fullerton M, Dilley R, Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93: 2578-2583, 1994
19. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 77: 863-868, 1995
20. Robert V, Besse S, Sabri A, Silvestre J-S, Assayag P, Thiem NV, Swynghedauw B, Delcayre C: Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 76: 729-738, 1997
21. Assayag P, Carre F, Chevalier B, Delcayre C, Mansier P, Swynghedauw B: Compensated cardiac hypertrophy: Arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc Res 34: 439-444, 1997
22. Sever PS: Clinical profile of the novel angiotensin II type 1 blocker candesartan cilexetil. J Hypertens 15[Suppl 6]: S9-S12, 1997
23. Inada Y, Wada T, Shibouta Y: Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 268: 1540-1547, 1994
24. Wada T, Kanagawa R, Ishimura Y, Inada Y, Nishikawa K: Role of angiotensin II in cerebrovascular and renal damage in deoxycorticosterone acetate-salt hypertensive rats. J Hypertens 13: 113-122, 1995
25. Karam H, Heudes D, Hess P, Gonzales MF, Loffler BM, Clozel M, Clozel P: Respective role of humoral factors and blood pressure in cardiac remodeling of DOCA hypertensive rats. Cardiovasc Res 31: 287-295, 1996
26. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Chatani F, Iwao H: Angiotensin II type 1 receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 273: 509-515, 1995
27. Engelmyer E, van Goor H, Edwards DR, Diamond JR: Differential mRNA expression of renal cortical tissue inhibitor of metalloproteinase-1, -2 and -3 in experimental hydronephrosis. J Am Soc Nephrol 5: 1675-1683, 1995
28. Ramires FJA, Sun Y, Weber KT: Myocardial fibrosis associated with aldosterone or angiotensin II administration: Attenuation by calcium channel blockade. J Mol Cell Cardiol 30: 475-483, 1998
29. Brilla CG, Scheer C, Rupp H: Renin-angiotensin system and myocardial collagen matrix: Modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens 15[Suppl 6]: S13-S19, 1997
30. 2+-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens 15: 1001-1009, 1997
31. Seyedi N, Xu XB, Nasjletti A, Hintze TH: Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26: 164-170, 1995
32. Kim S, Ohta K, Hamaguchi A, Yukimura T, Miura K, Iwao H: Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25: 1252-1259, 1995
33. Kagoshima T, Masuda J, Sutani T: The angiotensin II receptor antagonist, TCV-116, prevents myocardial hypertrophy in spontaneously hypertensive rats. Blood Press Supp 5: 89-93, 1994
34. Inada Y, Wada T, Ojima M: Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19: 1079-1099, 1997